Beyond instrument placement: Why supply chains are key to sustained AMR diagnostic readiness

19 November 2026

As the global health community marks World AMR Awareness Week 2026 under the theme “One Health, one action: Prevent AMR now,” the urgency of tackling antimicrobial resistance (AMR) is matched by renewed international commitments.

In May 2026, the World Health Assembly adopted the updated Global Action Plan on AMR (2026–2036), providing a framework for coordinated action, stronger surveillance and sustainable financing.

Yet translating these commitments into practical results remains a significant challenge, particularly in low- and middle-income countries (LMICs), where the burden of drug-resistant infections is disproportionately high. According to the World Health Organization, bacterial AMR is associated with more than 4.7 million deaths annually.

While investment in diagnostic technologies is essential, expanding laboratory capacity requires more than installing new equipment. Without reliable access to reagents, consumables, maintenance services, and other essential supplies, even advanced diagnostic instruments may be unable to deliver their intended benefits.

This highlights an important operational reality: behind every AMR test is a supply chain.

The operational challenge: equipping the laboratory and sustaining testing

Reliable diagnostics are fundamental to effective AMR diagnostic capacity, routine clinical care, treatment decisions, and antimicrobial stewardship. Microbiology testing and antimicrobial susceptibility testing (AST) help clinicians identify resistant infections and select appropriate treatments, while laboratory-generated data inform national and global surveillance efforts.

The WHO’s Global Antibiotic Resistance Surveillance Report 2025 reinforces the importance of strengthening laboratory surveillance systems and improving the availability and quality of resistance data to guide public health responses.

However, building sustainable diagnostic capacity presents challenges that extend well beyond the initial procurement of laboratory instruments.

These include managing diverse product portfolios, forecasting demand for specialized tests, navigating relatively low or fragmented purchasing volumes, and maintaining the availability of products with limited shelf lives or specific storage requirements.

In addition to procurement, logistics and importation present major hurdles in LMICs. Heavy reliance on overseas suppliers leaves health systems vulnerable to expensive freight and customs delays at ports of entry, which can disrupt testing services even when products are secured. Clear importation guidelines, closer engagement between Ministries of Health and Finance (MoH and MoF) to establish blanket waivers, applying for waivers earlier in the shipping process, and reducing cross-border barriers are essential to streamline customs clearance and sustain supply continuity.

An automated analyzer installed in a regional hospital cannot support patient care or resistance surveillance if the laboratory lacks the blood culture bottles, testing reagents, quality-control materials, or maintenance support needed to operate it.

The challenge, therefore, is not simply to expand diagnostic infrastructure, but to ensure that investments translate into reliable, sustained testing services.

​

Scientist working in the laboratory

Striking the strategic balance: Lessons from global health sourcing

Addressing these challenges requires procurement strategies that consider both initial equipment investment and the ongoing supply requirements of diagnostic services.

Between 2020 and 2026, the Partnership for Supply Chain Management (PFSCM) supported diagnostic procurement and delivery across 87 countries, delivering more than 23.1 million diagnostic units and tests valued at $628.17 million across a diverse portfolio of laboratory technologies, reagents, and consumables.

Within PFSCM’s microbiology portfolio across 27 countries, internal procurement data since 2020 illustrate the critical relationship between capital equipment investments and ongoing testing volume:

  • 46% of total microbiology procurement and AMR-related sequencing expenditure was allocated to automated diagnostic platforms, rapid gene detection systems, and blood culture analyzers 
  • 53% of total delivered testing units included daily reagents (43.34%) and routine consumables (10.05%) required to keep laboratory benches operational.

These figures illustrate the range of products required to support laboratory operations. They also reinforce the need to plan for the full diagnostic lifecycle—from initial technology selection and installation through to ongoing testing, quality assurance, and maintenance.

For AMR-related diagnostics, procurement decisions must account for more than product availability at the point of purchase. They must also consider whether laboratories can reliably access the products and services required to maintain testing capacity over time.

The future of diagnostic resilience: coordinated procurement

As countries work to implement national AMR action plans, sustainable financing and effective procurement strategies will become increasingly important.

The updated WHO Global Action Plan on AMR (2026–2036) emphasizes implementation, accountability, monitoring, and sustainable financing, reinforcing the need to translate international commitments into practical national action.

One approach worth greater consideration is coordinated procurement, which can help address fragmented demand, avoid high costs associated with dispersed, small-volume shipments, improve purchasing visibility, and support more predictable supply arrangements.

Three priorities deserve particular attention:

  1. Strengthening demand forecasting and procurement coordination

Better alignment of national and regional demand, supported by appropriate product standardization, can help procurement teams anticipate requirements, reduce fragmentation, and improve visibility for suppliers.

  1. Improving supply continuity and distribution planning

Effective inventory management, appropriate storage conditions, and well-planned distribution networks can help reduce the risk of stockouts while limiting product expiry and wastage.

  1. Planning for the complete diagnostic lifecycle
    Procurement strategies should consider equipment maintenance, spare parts, quality-control materials, training, and the continued availability of reagents and consumables alongside the initial acquisition of instruments.

These approaches require collaboration between governments, funders, laboratory professionals, manufacturers and supply chain partners. Their effectiveness will depend on local requirements, market conditions and the capacity of national health systems.

​

Translating commitment into action

The global AMR response has entered an important phase, with renewed commitments placing more emphasis on implementation and measurable progress.

Achieving these ambitions will require continued investment in prevention, surveillance, antimicrobial stewardship, diagnostics and health systems strengthening.

This focus on measurable outcomes comes at a critical juncture marked by the withdrawal of much of the international funding for global health. With reduced budgets from major international donors and institutions alongside the exit of key global health initiatives, the funding landscape is shifting dramatically. Consequently, financial responsibility is increasingly shifting away from historically dominant NGOs toward local governments and the Ministry of Health’s procurement.

For governments, donors and implementing partners, the question is no longer simply how to expand access to diagnostic technologies, but how to ensure that laboratories can continue using them effectively with limited resources.

Sustainable AMR diagnostic readiness is not achieved simply by installing an instrument. It depends on the systems, partnerships, and supply chains that keep testing services operational over time.

Considering these requirements from the outset, the global health community can help turn diagnostic investments into lasting capacity and strengthen the foundations of an effective AMR response.

​